Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection.
Roos
Jonathan C P
JC
Ostor
Andrew J K
AJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D039441:Integrin alpha4 / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D000069442:Natalizumab; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D039441:Integrin alpha4